The burgeoning popularity of semaglutide , initially for blood sugar control , is creating significant interest within the UK , prompting a notable shift in hormone trends. Access these medications remains a complex landscape, with NHS coverage currently limited and independent providers offering therapy at a substantial price. Questions are being